Chronic progressive calcineurin nephrotoxicity: an overstated concept.
作者信息
Matas Arthur J
机构信息
Division of Transplantation, Department of Surgery, University of Minnesota, MN, USA.
出版信息
Am J Transplant. 2011 Apr;11(4):687-92. doi: 10.1111/j.1600-6143.2011.03505.x.
Abstract
摘要
相似文献
1
Chronic progressive calcineurin nephrotoxicity: an overstated concept.慢性进行性钙调神经磷酸酶肾毒性：一个被夸大的概念。
Am J Transplant. 2011 Apr;11(4):687-92. doi: 10.1111/j.1600-6143.2011.03505.x.
2
Chronic calcineurin inhibitor nephrotoxicity-lest we forget.慢性钙调磷酸酶抑制剂肾毒性——切莫遗忘。
Am J Transplant. 2011 Apr;11(4):693-7. doi: 10.1111/j.1600-6143.2011.03504.x.
3
Calcineurin inhibitor nephrotoxicity.钙调神经磷酸酶抑制剂肾毒性。
Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. doi: 10.2215/CJN.04800908.
4
Outcomes after liver transplantation: chronic kidney disease.肝移植后的结果：慢性肾脏病。
Liver Transpl. 2009 Nov;15 Suppl 2:S70-4. doi: 10.1002/lt.21900.
5
The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.CARI指南。肾移植中的钙调神经磷酸酶抑制剂：肾毒性与钙调神经磷酸酶抑制剂。
Nephrology (Carlton). 2007 Feb;12 Suppl 1:S85-7. doi: 10.1111/j.1440-1797.2006.00733.x.
6
Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.零时活检中的动脉硬化是他克莫司诱导的慢性肾毒性的一个危险因素。
Nephrology (Carlton). 2015 Jul;20 Suppl 2:51-7. doi: 10.1111/nep.12461.
7
The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.钙调磷酸酶抑制剂相关性肾毒性的药物遗传学。
Ther Drug Monit. 2010 Aug;32(4):387-93. doi: 10.1097/FTD.0b013e3181e44244.
8
Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.他克莫司在肾移植中导致的 BK 病毒肾病和慢性钙调磷酸酶抑制剂毒性的患者内变异性。
Saudi J Kidney Dis Transpl. 2021 Mar-Apr;32(2):348-354. doi: 10.4103/1319-2442.335446.
9
The bumpy road of genomic medicine in transplantation: lessons from studies on calcineurin inhibitor nephrotoxicity.
Transplantation. 2012 Mar 27;93(6):578-9. doi: 10.1097/TP.0b013e31824db954.
10
Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.停用或减量钙调神经磷酸酶抑制剂对慢性移植肾肾病患者的长期影响。
Kidney Int. 2001 Apr;59(4):1567-73. doi: 10.1046/j.1523-1755.2001.0590041567.x.
引用本文的文献
1
Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation-A Transplant Nephrologist's Perspective.肾移植中钙调神经磷酸酶抑制剂相关肾毒性——一位移植肾病学家的观点
Acta Physiol (Oxf). 2025 May;241(5):e70047. doi: 10.1111/apha.70047.
2
A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation.肾移植维持免疫抑制方案的里程碑式研究综述。
Asian Biomed (Res Rev News). 2024 Jun 28;18(3):92-108. doi: 10.2478/abm-2024-0015. eCollection 2024 Jun.
3
Anuria after kidney transplantation diagnosed as early recurrence of focal segmental glomerulosclerosis combined with acute calcineurin inhibitor nephrotoxicity: a case report and literature review.肾移植后发生无尿，诊断为局灶节段性肾小球硬化症早期复发合并急性钙调磷酸酶抑制剂肾毒性：病例报告及文献复习。
BMC Nephrol. 2024 Apr 5;25(1):123. doi: 10.1186/s12882-024-03524-y.
4
Entering the Third Decade After Kidney Transplantation: Excellent Graft Function Refers to Superior Graft but Not Patient Survival.移植肾后进入第三个十年：优异的移植物功能意味着更好的移植物，但不是更好的患者生存。
Transpl Int. 2022 Oct 31;35:10675. doi: 10.3389/ti.2022.10675. eCollection 2022.
5
Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts.标准剂量与低剂量长半衰期他克莫司联合或不联合 ACEi/ARB 对肾移植组织学和功能的影响比较。
Am J Transplant. 2019 Jun;19(6):1730-1744. doi: 10.1111/ajt.15225. Epub 2019 Feb 1.
6
Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation.肾移植中钙调神经磷酸酶和雷帕霉素哺乳动物靶蛋白抑制剂的病理学
Kidney Int Rep. 2017 Oct 27;3(2):281-290. doi: 10.1016/j.ekir.2017.10.010. eCollection 2018 Mar.
7
Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014.钙调神经磷酸酶抑制剂暴露减少对新生供者特异性抗体（DSA）形成的影响：一项针对2007年至2014年间未接受免疫治疗的首次肾移植受者的队列研究。
BMC Nephrol. 2018 Sep 15;19(1):232. doi: 10.1186/s12882-018-1014-2.
8
Non-immunologic allograft loss in pediatric kidney transplant recipients.儿科肾移植受者的非免疫性同种异体移植物丢失。
Pediatr Nephrol. 2019 Feb;34(2):211-222. doi: 10.1007/s00467-018-3908-4. Epub 2018 Feb 26.
9
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.环孢素 A 减量与慢性移植肾肾病（3C 研究）：一项随机对照临床试验的结果
Am J Transplant. 2018 Jun;18(6):1424-1434. doi: 10.1111/ajt.14619. Epub 2018 Jan 9.
10
Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study.早期肾移植功能障碍（移植肾受威胁）：他克莫司继续使用与停用及使用西罗莫司预防移植肾失功的比较效果：一项以患者为中心的回顾性结局研究
Transplant Direct. 2016 Aug 11;2(9):e98. doi: 10.1097/TXD.0000000000000585. eCollection 2016 Sep.
本文引用的文献
1
An integrated view of molecular changes, histopathology and outcomes in kidney transplants.肾移植中分子变化、组织病理学和结果的综合观点。
Am J Transplant. 2010 Oct;10(10):2223-30. doi: 10.1111/j.1600-6143.2010.03268.x.
2
Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure.肾移植活检中管状萎缩区域的炎症：移植失败的有力预测指标。
Am J Transplant. 2010 Sep;10(9):2066-73. doi: 10.1111/j.1600-6143.2010.03240.x.
3
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.抗体介导的损伤是导致晚期肾脏移植物衰竭的主要决定因素的证据。
Transplantation. 2010 Jul 15;90(1):68-74. doi: 10.1097/TP.0b013e3181e065de.
4
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).一项比较贝利尤单抗与安慰剂治疗狼疮性肾炎的 III 期临床试验（CLEAR 研究）
Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x.
5
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).一项关于以贝利尤单抗为基础的免疫抑制方案与环孢素在肾移植受者中的疗效比较的 III 期研究（BENEFIT 研究）。
Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.
6
Predictors of renal dysfunction at 1 year in heart transplant patients.心脏移植患者 1 年内肾功能障碍的预测因素。
Transplantation. 2010 Apr 27;89(8):977-82. doi: 10.1097/tp.0b013e3181cbe024.
7
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.吗替麦考酚酯和皮质类固醇治疗的肾移植受者中，用胸腺球蛋白诱导和西罗莫司与他克莫司比较。
Transplantation. 2010 Jun 27;89(12):1511-7. doi: 10.1097/TP.0b013e3181db09e4.
8
Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up.从测量肾小球滤过率预测肝移植后肾功能衰竭：长达 15 年的随访回顾。
Transplantation. 2010 Jan 27;89(2):232-5. doi: 10.1097/TP.0b013e3181c42ff9.
9
The variable pathology of kidney disease after liver transplantation.肝移植后肾脏疾病的多变病理学。
Transplantation. 2010 Jan 27;89(2):215-21. doi: 10.1097/TP.0b013e3181c353e5.
10
Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.组织病理学簇可区分 CAN 或 CR 非特异性诊断中的亚组：DeKAF 研究的初步数据。
Am J Transplant. 2010 Feb;10(2):315-23. doi: 10.1111/j.1600-6143.2009.02943.x. Epub 2009 Dec 23.
Zotero 插件